Dabigatran etexilate

Drug Profile

Dabigatran etexilate

Alternative Names: BIBR 953; BIBR 953 ZW; BIBR-1048; BIBR-1048MS; Dabigatran; Dabigatran etexilate mesilate; Dabigatran etexilate mesylate; Pradax; Pradaxa; Pradaxar; Prazaxa

Latest Information Update: 22 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anticoagulants; Antithrombotics; Benzimidazoles; Pyridines; Small molecules
  • Mechanism of Action Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
  • Discontinued Acute coronary syndromes

Most Recent Events

  • 15 Nov 2017 Subgroup analysis efficacy data from a phase III trial in Stroke released by Boehringer Ingelheim
  • 18 Sep 2017 CHMP issued positive opinion to include to include RE-CIRCUIT data for dabigatran etexilate
  • 27 Aug 2017 Interim efficacy data from the phase III RE-DUAL PCI trial in Stroke presented at the Annual Congress of the European Society of Cardiology 2017 (ESC-CARD 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top